MetaVia Inc. (MTVA)
MTVA Stock Price Chart
Explore MetaVia Inc. interactive price chart. Choose custom timeframes to analyze MTVA price movements and trends.
MTVA Company Profile
Discover essential business fundamentals and corporate details for MetaVia Inc. (MTVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Aug 2016
Employees
9.00
Website
https://www.metaviatx.comCEO
Heon Kim Hyung
Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Financial Timeline
Browse a chronological timeline of MetaVia Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.26.
Earnings released on 7 Aug 2025
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%.
Earnings released on 14 May 2025
EPS came in at -$0.36 surpassing the estimated -$0.57 by +36.84%.
Earnings released on 27 Mar 2025
EPS came in at -$0.50 surpassing the estimated -$0.72 by +30.56%.
Earnings released on 7 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.73 by +24.66%.
Earnings released on 14 Aug 2024
EPS came in at -$1.85 falling short of the estimated -$1.38 by -34.06%.
Earnings released on 31 Mar 2024
EPS came in at -$1.32 falling short of the estimated -$1.10 by -19.93%.
Earnings released on 31 Dec 2023
EPS came in at -$1.05 falling short of the estimated -$0.84 by -24.53%.
Stock split effective on 21 Dec 2023
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at -$0.75 surpassing the estimated -$0.88 by +14.52%.
Earnings released on 30 Jun 2023
EPS came in at -$0.15 surpassing the estimated -$1.04 by +86.05%.
Earnings released on 31 Mar 2023
EPS came in at -$0.51 falling short of the estimated -$0.48 by -7.24%.
Earnings released on 31 Dec 2022
EPS came in at $39.44 surpassing the estimated -$9.63 by +509.41%.
Earnings released on 30 Sept 2022
EPS came in at -$28.02 .
Stock split effective on 13 Sept 2022
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2022
EPS came in at -$29.73 .
Earnings released on 31 Mar 2022
EPS came in at -$25.88 .
Earnings released on 31 Dec 2021
EPS came in at -$39.62 .
Earnings released on 30 Sept 2021
EPS came in at -$37.27 .
Earnings released on 30 Jun 2021
EPS came in at -$42.77 .
Earnings released on 31 Mar 2021
EPS came in at -$36.91 .
Earnings released on 31 Dec 2020
EPS came in at -$109.80 .
Earnings released on 30 Sept 2020
EPS came in at -$44.62 .
MTVA Stock Performance
Access detailed MTVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.